Dr.
Lokeswara Rao Sajja, Senior Consultant Cardiothoracic Surgeon at STAR Hospitals
and Chairman of the Sajja Heart Foundation, has been inducted as an Associate
Member of Sigma Xi, The Scientific Research Honor Society—one of the
world’s oldest and most respected organizations dedicated to the advancement of
science and research.
Founded
in 1886 at Cornell University, USA, Sigma Xi has a long legacy of supporting
excellence in scientific research and fostering collaboration among researchers
across disciplines. The society boasts over 200 Nobel Laureates among
its past and present members, including eminent scientists like Albert
Einstein, Richard Feynman, Barbara McClintock, Francis Crick, andJennifer
Doudna among others.
Membership
in Sigma Xi is offered by invitation only, extended to individuals who have
demonstrated significant contributions to scientific research. Dr. Sajja was
invited and recognized for his pioneering work in cardiovascular surgery,
including his leadership in conducting India’s first multi-centre randomized
trial in cardiac surgery (PROMOTE Patency Trial) and designing a
mechanical heart valve that does not require long-term anticoagulation,
which holds both US and Indian patents.
Speaking
on the occasion, Dr. Sajja said, “I am honored to be invited into Sigma Xi,
which represents the highest ideals of scientific inquiry and ethical research.
This recognition strengthens my resolve to promote collaborative and
patient-centered cardiovascular research from India on a global platform.”
Dr.
Sajja’s induction into Sigma Xi places him among an elite global fraternity of
researchers committed to fostering innovation and advancing knowledge for the
benefit of humanity. His association with Sigma Xi is also expected to inspire
young Indian scientists, clinicians, and students to pursue evidence-based
research with international standards.
This
development is a proud moment for India’s scientific community and underscores
the growing global recognition of Indian contributions in the fields of medical
innovation, clinical research, and translational science.